Lambert-Eaton Myasthenic Syndrome Epidemiology Forecast to 2030

(Albany, US) DelveInsight ha s launched a new report on Lambert-Eaton Myasthenic Syndrome Epidemiology Forecast to 2030

DelveInsight’s Lambert-Eaton Myasthenic Syndrome Epidemiology Forecast to 2030‘ report delivers an in-depth understanding of the disease, historical and forecasted Lambert-Eaton Myasthenic Syndrome epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Lambert-Eaton Myasthenic Syndrome epidemiology
Lambert-Eaton Myasthenic Syndrome epidemiology

 

Download For Free Sample Page:- https://www.delveinsight.com/sample-request/lambert-eaton-myasthenic-syndrome-epidemiology-forecast

KEY FACT FROM THE REPORT

  • According to the National Organization of Rare Disorders, there are approximately 400 known cases of LEMS in the United States. It is scarce in the pediatric population, with only 11 affected children reported in the literature.
  • According to the literature review, in 50% of the patients, LEMS is a paraneoplastic manifestation and is caused by small cell lung carcinoma (SCLC) (Nils Erik Gilhus)
  • The P-LEMS form is more frequent among men and occurs at a median age of 60 years while the presentation of A-LEMS is more balanced between males and females (Elrington GM et al.)
  • According to the epidemiologic studies of LEMS, the LEMS point prevalence was estimated to be 2.5 and 2.34 per million, with an incidence of 0.5, 0.4, and 0.2 per million (Wirtz PW et al., Somnier FE et al.)

 

Scope of the Report

  • The Lambert-Eaton Myasthenic Syndrome report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
  • The Lambert-Eaton Myasthenic Syndrome Epidemiology Report and Model provide an overview of the risk factors and global trends of Lambert-Eaton Myasthenic Syndrome in the seven major markets (7MM:US, France, Germany, Italy, Spain, UK, and Japan)
  • The report provides insight about the historical and forecasted patient pool of Lambert-Eaton Myasthenic Syndrome in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan
  • The report helps to recognize the growth opportunities in the 7MM with respect to the patient population
  • The report assesses the disease risk and burden and highlights the unmet needs of Lambert-Eaton Myasthenic Syndrome
  • The report provides the segmentation of the Lambert-Eaton Myasthenic Syndrome epidemiology.

 

Reasons to buy

  • The Lambert-Eaton Myasthenic Syndrome Epidemiology report will allow the user to –
  • Develop business strategies by understanding the trends shaping and driving the global Lambert-Eaton Myasthenic Syndrome market
  • Quantify patient populations in the global Lambert-Eaton Myasthenic Syndrome market to improve product design, pricing, and launch plans
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Lambert-Eaton Myasthenic Syndrome therapeutics in each of the markets covered
  • Understand the magnitude of Lambert-Eaton Myasthenic Syndrome population by its epidemiology
  • The Lambert-Eaton Myasthenic Syndrome Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources.

MAJOR KEY PLAYERS OF THE REPORT

  • Catalyst Pharmaceuticals
  • Jacobus Pharmaceuticals

NAME OF DRUGS COVERED IN THE REPORT

  • Firdapse
  • Ruzurgi

Table of content

1. Key Insights

2. Executive Summary of Lambert-Eaton Myasthenic Syndrome

3. Lambert-Eaton Myasthenic Syndrome: Disease Background and Overview

3.1. Introduction

3.2. Sign and Symptoms

3.3. Pathophysiology

3.4. Risk Factors

3.5. Diagnosis

4. Patient Journey

5. Epidemiology and Patient Population

5.1. Epidemiology Key Findings

5.2. Assumptions and Rationale: 7MM

5.3. Epidemiology Scenario: 7MM

5.3.1. Lambert-Eaton Myasthenic Syndrome Epidemiology Scenario in the 7MM (2017- 2030)

5.4. United States Epidemiology

5.4.1. Lambert-Eaton Myasthenic Syndrome Epidemiology Scenario in the United States (2017- 2030)

5.5. EU-5 Country-wise Epidemiology

5.5.1. Germany Epidemiology

5.5.1.1. Lambert-Eaton Myasthenic Syndrome Epidemiology Scenario in Germany (2017- 2030)

5.5.2. France Epidemiology

5.5.2.1. Lambert-Eaton Myasthenic Syndrome Epidemiology Scenario in France (2017- 2030)

5.5.3. Italy Epidemiology

5.5.3.1. Lambert-Eaton Myasthenic Syndrome Epidemiology Scenario in Italy (2017- 2030)

5.5.4. Spain Epidemiology

5.5.4.1. Lambert-Eaton Myasthenic Syndrome Epidemiology Scenario in Spain (2017- 2030)

5.5.5. United Kingdom Epidemiology

5.5.5.1. Lambert-Eaton Myasthenic Syndrome Epidemiology Scenario in the United Kingdom (2017-2030)

5.6. Japan Epidemiology

5.6.1. Lambert-Eaton Myasthenic Syndrome Epidemiology Scenario in Japan (2017- 2030)

6. Treatment Algorithm, Current Treatment, and Medical Practices

6.1. Lambert-Eaton Myasthenic Syndrome Treatment and Management

6.2. Lambert-Eaton Myasthenic Syndrome Treatment Algorithm

7. KOL Views

8. Unmet Needs

9.  Appendix

9.1. Bibliography

9.2. Report Methodology

10. DelveInsight Capabilities

11. Disclaimer

12. About DelveInsight

Related Reports

About DelveInsight

DelveInsight is a premier Business Consulting and Market Research firm, focused exclusively on the life science segment. With a wide array of smart end-to-end solutions, the firm helps the global Pharmaceutical, Bio-Tech and Medical devices companies formulate prudent business decisions for improving their performances to stay ahead of the competitors.

 

Contact us:

Shruti Thakur
[email protected]
+91-9650213330
DelveInsight

Related posts